Literature DB >> 18835319

Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice.

Virginie M G Renoux1, Maxime J J Fleury, Latifa Bousarghin, Julien Gaitan, Pierre-Yves Sizaret, Antoine Touzé, Pierre Coursaget.   

Abstract

A hepatitis E virus (HEV) vaccine would be valuable to reduce the morbidity and mortality associated with the infection in endemic areas. HEV pseudocapsids and epidermal delivery of HEV ORF2 DNA vaccine by gene-gun have been shown to confer protection against virus challenge in monkeys. Vectorization of a DNA vaccine by virus-like particles is a new immunization approach. We report here the successful immunization of mice with two ORF2 genes encapsidated into human papillomavirus type 31 virus-like particles. The HEV genes ORF2(112-660) and ORF2(112-608) were optimized for expression in mammalian cells and inserted in a baculovirus-derived vector for expression in insect cells. When expressed in Sf21 insect cells, ORF2(112-660) led to the production of irregular 15 nm particles that accumulated in the cytoplasm of the cells, whereas ORF2(112-608) induced the production of 18nm particles that were present in both the cell culture medium and the cell cytoplasm. Anti-HEV immune responses were higher for the 15 nm particles (HEV112-660) than that for to the 18 nm particles (HEV112-608). Delivery into mice of two HEV ORF2 genes via a papillomavirus VLP was very effective in the induction of anti-HEV antibodies. In addition, an effective immune response to human papillomavirus capsids occurred. These engineered pseudoviruses were thus demonstrated to induce immune responses to both hepatitis E virus and human papillomavirus when they were administered to mice intramuscularly.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18835319     DOI: 10.1016/j.vaccine.2008.09.035

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

Review 1.  Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy.

Authors:  Tamas Virag; Sylvain Cecchini; Robert M Kotin
Journal:  Hum Gene Ther       Date:  2009-08       Impact factor: 5.695

2.  Human papillomavirus type 16 pseudovirions with few point mutations in L1 major capsid protein FG loop could escape actual or future vaccination for potential use in gene therapy.

Authors:  Maxime J J Fleury; Antoine Touzé; Pierre Coursaget
Journal:  Mol Biotechnol       Date:  2014-05       Impact factor: 2.695

3.  High hepatitis E virus seroprevalence in forestry workers and in wild boars in France.

Authors:  Audrey Carpentier; Hélène Chaussade; Emma Rigaud; Josefa Rodriguez; Camille Berthault; Franck Boué; Mauro Tognon; Antoine Touzé; Nathalie Garcia-Bonnet; Patrick Choutet; Pierre Coursaget
Journal:  J Clin Microbiol       Date:  2012-06-20       Impact factor: 5.948

4.  Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.

Authors:  Nicolas Combelas; Emilie Saussereau; Maxime J J Fleury; Tatiana Ribeiro; Julien Gaitan; Diego F Duarte-Forero; Pierre Coursaget; Antoine Touzé
Journal:  J Transl Med       Date:  2010-03-24       Impact factor: 5.531

5.  Liver-specific Gene Delivery Using Engineered Virus-Like Particles of Hepatitis E Virus.

Authors:  Eun Byul Lee; Jung-Hee Kim; Wonhee Hur; Jung Eun Choi; Sung Min Kim; Dong Jun Park; Byung-Yoon Kang; Gil Won Lee; Seung Kew Yoon
Journal:  Sci Rep       Date:  2019-02-07       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.